Biota
-
Biotage launches extraction applications
Biotage launched a series of application notes utilizing the industry-standard RapidTrace SPE Workstation. Applications include extractions from plasma, urine and whole blood, typically assayed in clinical and forensic protocols. Additionally, a…
Biota | 09 March 2011
-
Biotage offers PEG resins for solid phase peptide synthesis
Biotage is adding ChemMatrix resins to its offering of peptide synthesis and purification products. ChemMatrix is a patented 100 percent PEG resin from Matrix Innovation that offers substantial advantages over traditional PS and PEG based resins for…
Biota | 17 February 2011
-
Biotage Releases Catalog for Sample Preparation Products and Applications
Biotage has released its Sample Preparation Catalog. The 176-page catalog includes a range of products including Bioanalytical and Clinical applications. This catalog offers an applications index with links, along with comprehensive information t…
Biota | 07 May 2010
-
Biotage Reduces Solvent Use in Flash Purification
Biotage, a supplier of tools and technology for medicinal and analytical chemistry, has announced the launch of enhanced Gradient Optimization (GO) technology for their Isolera flash purification product line. This technology can reduce solvent use a…
Biota | 19 April 2010
-
Biotage Announces Parallel Peptide Synthesizer
Biotage has announced the global launch of the Syro Wave; a microwave and parallel peptide synthesizer. The product is a result of the joint development project with MultiSynTech. It combines the performance of the established MultiSynTech roboti…
Biota | 09 April 2010
-
Biotage Partners with JMS for Distribution in Australia and New Zealand
Biotage has announced a partnership with John Morris Scientific (JMS), a distributor in Australia and New Zealand. Andre Wyzenbeek, marketing director of John Morris Scientific commented, "Biotage is prominent in the local medicinal chemistry com…
Biota | 17 February 2010
-
Biota Acquires Antibacterial Assets of Prolysis
Biota Holdings has announced the acquisition of the key assets and programs of Prolysis, an antibacterial drug discovery company located in Oxford, England. Prolysis has two primary projects that are focused on new antibiotics for multiple drug r…
Biota | 26 November 2009
-
Biota to Acquire Antibacterial Assets of MaxThera
Biota Holdings has announced the acquisition of the assets and drug development programs of MaxThera, an antibacterial drug discovery company located in Boston, US. The acquisition is subject to the satisfaction of certain conditions which the former…
Biota | 20 November 2009
-
Australian Government Stockpiles 1.6 million Courses of Relenza
Biota Holdings has announced that the Australian government has purchased an additional 1.6 million courses of Relenza for the National Medical Stockpile to bolster supplies of antiviral drugs to treat pandemic influenza. The purchase cost is A$43 mi…
Biota | 08 June 2009
-
Relenza: Sales in Q1
Biota Holdings has received notification from GlaxoSmithKline (GSK) that Relenza sales were US$327.5 million and indicative royalties were US$22.9 million, for the three months ended 31 March 2009. Indicative royalties for the nine months to 31 Ma…
Biota | 04 May 2009
